STOCK MARKET BSE NSE

Exceptional Income Drives Biocon Net Up 79%

Biocon’s net profit rose 79% to Rs 361 crore compared to Rs 201.5 crore in the corresponding period of the previous year’s March quarter.

Published: 28th April 2016 06:41 AM  |   Last Updated: 28th April 2016 06:41 AM   |  A+A-

BENGALURU: Biocon’s net profit rose 79% to Rs 361 crore compared to Rs 201.5 crore in the corresponding period of the previous year’s March quarter.

The performance was led by an exceptional item, improved sales at its contract research arm Syngene International  and a moderate growth at its bio-pharmaceutical division. The company posted revenue 17% higher during the quarter to Rs 979 crore from Rs 838 crore in the year-ago period. Biocon saw an exceptional income of Rs 268 crore during the quarter.

Excluding that amount, the net profit for the March quarter was Rs 105 crore. Biocon said the exceptional item was on account of the previously deferred amounts of Rs 268 crore relating to clinical trial and development activities of insulin products with its Mexican partner, Lab PiSA. For the year to March, its net profit rose 80% to Rs 896 crore, while sales rose 13% to Rs 3,451 crore.

The firm’s contract research arm Syngene had contributed about a third to Biocon revenues. Meanwhile,Biocon has appointed former Sebi chief  M  Damodaran as additional independent director. 

Stay up to date on all the latest Business news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp